Agenus(AGEN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Agenus Reports Second Quarter 2024 Operational and Financial Results • Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC • Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease • Commenced Interactions with Global Regulatory Authorities for BOT/BAL Approval Pathways • Data from ESMO GI Demonstrate Pathologic Complete Responses with BOT/BAL Therapy in Neoa ...